Stuart A. Arbuckle - 23 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
23 Feb 2024
Net transactions value
-$4,178,432
Form type
4
Filing time
27 Feb 2024, 16:37:27 UTC
Previous filing
23 Feb 2024
Next filing
17 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $2,035,458 -4,714 -7.9% $431.79 54,725 23 Feb 2024 Direct
transaction VRTX Common Stock Sale $2,142,974 -5,034 -9.2% $425.70 49,691 26 Feb 2024 Direct F1
holding VRTX Common Stock 140 23 Feb 2024 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.